USFDA concludes pre-approval inspection at Visakhapatnam facility of Gland Pharma

25 Feb 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded Pre-approval inspection (PAI) for Sterile APIs at Gland Pharma’s facility at JNPC, Visakhapatnam. The inspection was conducted from February 19, 2025 to February 25, 2025.

The said inspection was concluded with three form 483 observations. These observations are procedural in nature. The corrective and preventive actions for these observations will be submitted to the USFDA within the stipulated period. The observations issued are neither repeated observations nor related to data integrity. 

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Gland Pharma Share Price

1412.95 -38.40 (-2.65%)
28-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1841.80
Dr. Reddys Lab 1199.70
Cipla 1554.40
Lupin 2107.70
Zydus Lifesciences 885.85
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...